ERA Congress: Semaglutide linked to better quality of life in diabetes and kidney disease, FLOW trial shows

Contributed by: PR Newswire

Tags

ERA-CONGRESS-FLOW

More Like This

61st ERA Congress: Semaglutide significantly reduces risk of major kidney disease events, cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease, groundbreaking study reveals

EADV Congress 2024: Semaglutide improves outcomes for obese patients with common skin condition, new study shows

PR Newswire associated0

FDA approves Novo Nordisk's oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event

UEG Week: Novel procedure combined with semaglutide may eliminate insulin dependency in type 2 diabetes

PR Newswire associated0

Novo Nordisk's Wegovy® (semaglutide 2.4 mg) was associated with liver health-related benefits not solely based on weight loss in adult patients with MASH with liver scarring, according to a new post hoc analysis

ESGE Days 2026: Endoscopic procedure associated with greater short-term weight loss than oral semaglutide, study finds

People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data

Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-1